Depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder Depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder
Conditions
Interventions
Transcranial Magnetic Stimulation (TMS), Theta Burst Stimulation (TBS), Electroconvulsive Therapy
(ECT), or Magnetic Seisure Therapy (MST)
For patients with MDD or BD in depressive
episode:
1)Tran
2)Electroconvulsive therapy (ECT) will
be administered with brief or ultra-brief
pulse on the bilateral prefrontal or temporal
lobes or right hemisphere according to the
patient's condition, effica
3) Magnetic Seizure Therapy (MST) will be
administered with 25-100Hz pulse on the
bilateral prefrontal or vertex regions
according to the patient's condition, efficacy
and tolerability.
For patien
2)MST will be administered with 25-100Hz pulse
on the bilateral prefrontal or vertex regions
according to the patient's condition, efficacy
and tolerability.
For patients with OCD:
1)TMS will be pe
D004561, D050781, D004565
Neuromodulation therapy, transcranial magnetic stimulation, theta burst stimulation, electroconvulsive therapy, magnetic seizure therapy
Sponsors
Daisuke Hayashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For patients with major depressive disorder (MDD) those who: 1)are diagnosed as MDD in depressive episode in DSM-5; 2)are aged >=18; 3)got a total score of >=20 in HAMD-17; and 4)did not respond to pharmacotherapy conducted as standard treatments for patients with MDD. For patients with bipolar disorder (BD), those who: 1)are diagnosed as BD in in depressive episode in DSM-5; 2)are aged >=18; 3)got a total score of >=20 in HAMD-17; and 4)did not respond to pharmacotherapy conducted as standard treatments for patients with BD in depressive episode. For patients with schizophrenia (SZ), those who: 1)are diagnosed as SZ in DSM-5; 2)are aged >=18; 3)got a total score of >=60 in PANSS; and 4)did not respond to pharmacotherapy conducted as standard treatments for patients with SZ. For patients with obsessive-compulsive disorder (OCD), those who: 1)are diagnosed as OCD in DSM-5; 2)are aged >=18; 3)got a total score of >=20 in YBOCS; and 4)did not respond to pharmacotherapy and/or psychotherapy conducted as standard treatments for patients with OCD.
Exclusion criteria
Exclusion criteria: 1)patients who have concurrent mental disorders such as autism spectrum disorder (ASD), attention deficit hyperactive disorder (ADHD), post-traumatic stress disorder (PTSD), dissociative disorder, eating disorder, substance-related disorder, and/or personality disorder; 2)patients in pregnancy or lactating patients; 3)patients with a present or past history of convulsive disorder (epilepsy, etc.) and their first degree relatives with the same disorder; 4)patients with a present or past history of neurological disorders or organic brain disorders; 5)patients having magnetic substance which can be hardly extracted such as a pacemaker, artificial inner ear, and intracranial clip; 6)patients having physical disease such as severe metabolic disease and endocrine disease; 7)patients with severe suicidal ideation; or 8)patients deemded inappropriate to participate by judgement of principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For patients with MDD and BD with depressive episode: 1)Change in the scores of Montgomery Asberg depression rating scale (MADRS) before and after the intervention in acute treatment period. For patients with SZ with severe cognitive impairment: 1)Changes in the scores of the BACS before and after the intervention in acute treatment period. For patients with SZ with psychosis: 1)Changes in the scores of the Positive and Negative Syndrome Scale (PANSS) before and after the intervention in acute treatment period. For patients with OCD: 1)Changes in the scores of the Yale Brown Obsessive Compulsive Scale (YBOCS) before and after the intervention in acute treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| For patients with MDD and BD with depressive episode: 1)Change in the scores of MADRS, HAMD, BACS, TMT, Stroop, and Clinical global impressions (CGI) in acute treatment and observation periods; 2)Response and remission rates after the intervention 3)Relapse/recurrence rate in observation period and duration of time from the end of intervention to relapse/recurrence. For patients with SZ: 1)Change in the scores of BACS, TMT, Stroop, PANSS, and CGI in acute treatment and observation periods; 2)Response and non-response rates after the intervention 3)Response and non-response rates in observation period. For patients with OCD: 1)Change in the scores of YBOCS, BACS, TMT, Stroop, HAMD, and CGI in acute treatment and observation periods; 2)Response, partial response, and non-response rates after the intervention 3)Response, partial response, and non-response rates in observation period. | — |
Contacts
Public ContactMatsuo Junko
National Center of Neurology and Psychiatry Hospital
Outcome results
None listed